Affordable Access

Clinical experience with the Bicarbon heart valve prosthesis

Authors
Publisher
BioMed Central
Publication Date
Source
PMC
Keywords
  • Research Article

Abstract

1749-8090-2-8.fm ral ss BioMed CentJournal of Cardiothoracic Surgery Open AcceResearch article Clinical experience with the Bicarbon heart valve prosthesis Yoshio Misawa*, Tsutomu Saito, Hiroaki Konishi, Shin-ichi Oki, Yuichiro Kaminishi, Yasuhito Sakano, Hideki Morita and Kei Aizawa Address: Division of Cardiovascular Surgery, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, JAPAN Email: Yoshio Misawa* - tcvmisa@jichi.ac.jp; Tsutomu Saito - cvsricky@jichi.ac.jp; Hiroaki Konishi - tcvhiro@jichi.ac.jp; Shin- ichi Oki - tcvohki@jichi.ac.jp; Yuichiro Kaminishi - tcvkamyu@jichi.ac.jp; Yasuhito Sakano - tcvsaka@jichi.ac.jp; Hideki Morita - udon@jichi.ac.jp; Kei Aizawa - tcvai@jichi.ac.jp * Corresponding author Abstract Bacground: We have previously reported mid-term results of a study, which ended in January 2000, on the Bicarbon valve. The study concluded that the valve showed excellent clinical results, associated with a low incidence of valve-related complications. In the present study, the same patients were prospectively followed for an additional 5 years. Methods: Forty-four patients had aortic valve replacement (AVR), 48 had mitral valve replacement (MVR), and 13 had both aortic and mitral valve replacement (DVR). The mean age of the 105 patients was 61.2 ± 11.3 years. The mean follow-up was 6.1 ± 1.9 years with a cumulative follow- up of 616 patient-years. Results: There were 5 early deaths (4.7%: 4 in the AVR group and 1 in the MVR group) and 21 late deaths (3.4%/patient-year: 5 valve related deaths and 16 valve unrelated deaths). Survival at 8 years was 75.2 ± 7.0% in the AVR group, 76.6 ± 6.2% in the MVR group, and 55.4 ± 16.1% in the DVR group. The linearized incidence of thrombo-embolic complications, hemorrhagic complications, and paravalvular leaks in all patients was 0.65 ± 1.48%, 0.81 ± 1.69%, and 0.16 ± 0.54%/patient-year respectively. No other complications were observed. Conclusion: The Bicarbon prosthetic heart valve has sho

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F